Literature DB >> 20300106

Targeting metabolic transformation for cancer therapy.

Daniel A Tennant1, Raúl V Durán, Eyal Gottlieb.   

Abstract

Cancer therapy has long relied on the rapid proliferation of tumour cells for effective treatment. However, the lack of specificity in this approach often leads to undesirable side effects. Many reports have described various 'metabolic transformation' events that enable cancer cells to survive, suggesting that metabolic pathways might be good targets. There are currently several drugs under development or in clinical trials that are based on specifically targeting the altered metabolic pathways of tumours. This Review highlights pathways against which there are already drugs in different stages of development and also discusses additional druggable targets.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20300106     DOI: 10.1038/nrc2817

Source DB:  PubMed          Journal:  Nat Rev Cancer        ISSN: 1474-175X            Impact factor:   60.716


  147 in total

1.  A mitochondria-K+ channel axis is suppressed in cancer and its normalization promotes apoptosis and inhibits cancer growth.

Authors:  Sébastien Bonnet; Stephen L Archer; Joan Allalunis-Turner; Alois Haromy; Christian Beaulieu; Richard Thompson; Christopher T Lee; Gary D Lopaschuk; Lakshmi Puttagunta; Sandra Bonnet; Gwyneth Harry; Kyoko Hashimoto; Christopher J Porter; Miguel A Andrade; Bernard Thebaud; Evangelos D Michelakis
Journal:  Cancer Cell       Date:  2007-01       Impact factor: 31.743

2.  Cancer patients opt for unapproved drug.

Authors:  Helen Pearson
Journal:  Nature       Date:  2007-03-29       Impact factor: 49.962

3.  Oxidation of C14-labeled carbohydrate intermediates in tumor and normal tissue.

Authors:  R E OLSON
Journal:  Cancer Res       Date:  1951-08       Impact factor: 12.701

4.  Phase II trial of temsirolimus (CCI-779) in recurrent glioblastoma multiforme: a North Central Cancer Treatment Group Study.

Authors:  Evanthia Galanis; Jan C Buckner; Matthew J Maurer; Jeffrey I Kreisberg; Karla Ballman; J Boni; Josep M Peralba; Robert B Jenkins; Shaker R Dakhil; Roscoe F Morton; Kurt A Jaeckle; Bernd W Scheithauer; Janet Dancey; Manuel Hidalgo; Daniel J Walsh
Journal:  J Clin Oncol       Date:  2005-07-05       Impact factor: 44.544

Review 5.  Hypoxia and adaptive landscapes in the evolution of carcinogenesis.

Authors:  Robert J Gillies; Robert A Gatenby
Journal:  Cancer Metastasis Rev       Date:  2007-06       Impact factor: 9.264

6.  ATP citrate lyase inhibition can suppress tumor cell growth.

Authors:  Georgia Hatzivassiliou; Fangping Zhao; Daniel E Bauer; Charalambos Andreadis; Anthony N Shaw; Dashyant Dhanak; Sunil R Hingorani; David A Tuveson; Craig B Thompson
Journal:  Cancer Cell       Date:  2005-10       Impact factor: 31.743

7.  Tumor growth in patients with tuberous sclerosis complex on the ketogenic diet.

Authors:  Catherine J Chu-Shore; Elizabeth A Thiele
Journal:  Brain Dev       Date:  2009-05-13       Impact factor: 1.961

8.  Synergistic antipancreatic tumor effect by simultaneously targeting hypoxic cancer cells with HSP90 inhibitor and glycolysis inhibitor.

Authors:  Xianhua Cao; Mark Bloomston; Tao Zhang; Wendy L Frankel; Guang Jia; Bing Wang; Nathan C Hall; Regina M Koch; Hao Cheng; Michael V Knopp; Duxin Sun
Journal:  Clin Cancer Res       Date:  2008-03-15       Impact factor: 12.531

Review 9.  Double role for pyruvate kinase type M2 in the expansion of phosphometabolite pools found in tumor cells.

Authors:  E Eigenbrodt; M Reinacher; U Scheefers-Borchel; H Scheefers; R Friis
Journal:  Crit Rev Oncog       Date:  1992

10.  Hypoxia response elements in the aldolase A, enolase 1, and lactate dehydrogenase A gene promoters contain essential binding sites for hypoxia-inducible factor 1.

Authors:  G L Semenza; B H Jiang; S W Leung; R Passantino; J P Concordet; P Maire; A Giallongo
Journal:  J Biol Chem       Date:  1996-12-20       Impact factor: 5.157

View more
  445 in total

1.  CD147 subunit of lactate/H+ symporters MCT1 and hypoxia-inducible MCT4 is critical for energetics and growth of glycolytic tumors.

Authors:  Renaud Le Floch; Johanna Chiche; Ibtissam Marchiq; Tanesha Naiken; Tanesha Naïken; Karine Ilc; Karine Ilk; Clare M Murray; Susan E Critchlow; Danièle Roux; Marie-Pierre Simon; Jacques Pouysségur
Journal:  Proc Natl Acad Sci U S A       Date:  2011-09-19       Impact factor: 11.205

2.  Systemic elevation of PTEN induces a tumor-suppressive metabolic state.

Authors:  Isabel Garcia-Cao; Min Sup Song; Robin M Hobbs; Gaelle Laurent; Carlotta Giorgi; Vincent C J de Boer; Dimitrios Anastasiou; Keisuke Ito; Atsuo T Sasaki; Lucia Rameh; Arkaitz Carracedo; Matthew G Vander Heiden; Lewis C Cantley; Paolo Pinton; Marcia C Haigis; Pier Paolo Pandolfi
Journal:  Cell       Date:  2012-03-06       Impact factor: 41.582

3.  Targeting energetic metabolism: a new frontier in the pathogenesis and treatment of pulmonary hypertension.

Authors:  Rubin M Tuder; Laura A Davis; Brian B Graham
Journal:  Am J Respir Crit Care Med       Date:  2011-11-10       Impact factor: 21.405

Review 4.  Stable isotope-resolved metabolomics and applications for drug development.

Authors:  Teresa W-M Fan; Pawel K Lorkiewicz; Katherine Sellers; Hunter N B Moseley; Richard M Higashi; Andrew N Lane
Journal:  Pharmacol Ther       Date:  2011-12-23       Impact factor: 12.310

Review 5.  Dysregulated pH: a perfect storm for cancer progression.

Authors:  Bradley A Webb; Michael Chimenti; Matthew P Jacobson; Diane L Barber
Journal:  Nat Rev Cancer       Date:  2011-08-11       Impact factor: 60.716

6.  Prevention of Dietary-Fat-Fueled Ketogenesis Attenuates BRAF V600E Tumor Growth.

Authors:  Siyuan Xia; Ruiting Lin; Lingtao Jin; Liang Zhao; Hee-Bum Kang; Yaozhu Pan; Shuangping Liu; Guoqing Qian; Zhiyu Qian; Evmorfia Konstantakou; Baotong Zhang; Jin-Tang Dong; Young Rock Chung; Omar Abdel-Wahab; Taha Merghoub; Lu Zhou; Ragini R Kudchadkar; David H Lawson; Hanna J Khoury; Fadlo R Khuri; Lawrence H Boise; Sagar Lonial; Benjamin H Lee; Brian P Pollack; Jack L Arbiser; Jun Fan; Qun-Ying Lei; Jing Chen
Journal:  Cell Metab       Date:  2017-01-12       Impact factor: 27.287

7.  Liver kinase B1 expression promotes phosphatase activity and abrogation of receptor tyrosine kinase phosphorylation in human cancer cells.

Authors:  Imoh S Okon; Kathleen A Coughlan; Ming-Hui Zou
Journal:  J Biol Chem       Date:  2013-11-27       Impact factor: 5.157

8.  A distinct metabolic signature of human colorectal cancer with prognostic potential.

Authors:  Yunping Qiu; Guoxiang Cai; Bingsen Zhou; Dan Li; Aihua Zhao; Guoxiang Xie; Houkai Li; Sanjun Cai; Dong Xie; Changzhi Huang; Weiting Ge; Zhanxiang Zhou; Lisa X Xu; Weiping Jia; Shu Zheng; Yun Yen; Wei Jia
Journal:  Clin Cancer Res       Date:  2014-02-13       Impact factor: 12.531

9.  Metabolic signature identifies novel targets for drug resistance in multiple myeloma.

Authors:  Patricia Maiso; Daisy Huynh; Michele Moschetta; Antonio Sacco; Yosra Aljawai; Yuji Mishima; John M Asara; Aldo M Roccaro; Alec C Kimmelman; Irene M Ghobrial
Journal:  Cancer Res       Date:  2015-03-13       Impact factor: 12.701

10.  Acetyl-CoA carboxylase rewires cancer metabolism to allow cancer cells to survive inhibition of the Warburg effect by cetuximab.

Authors:  Jingtao Luo; Yun Hong; Yang Lu; Songbo Qiu; Bharat K R Chaganty; Lun Zhang; Xudong Wang; Qiang Li; Zhen Fan
Journal:  Cancer Lett       Date:  2016-09-28       Impact factor: 8.679

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.